ZNTL

#3419
Zentalis Pharmaceuticals, Inc. - common stock
3.7 4 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.72
3.74
Intervallo Annuale
1.21
6.95
Variazione giornaliera
-1.58%
Variazione Mensile
-21.92%
Variazione di 6 mesi
+59.15%
Variazione Annuale
+120.00%
Chiusura Precedente
3.8 0
Open
3.7 3
Minimo
3.7 2
Massimo
3.7 4
Volume
85
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Zentalis Pharmaceuticals, Inc. current report, Q2 FY2025

Full document

Zentalis Pharmaceuticals, Inc. (ZNTL) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated June 17, 2025, reports the results of the Company's 2025 Annual Meeting of Stockholders. The meeting was held on June 17, 2025, with 58,212,103 shares present, representing approximately 80.9% of outstanding common stock as of the April 21, 2025 record date.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

The following proposals were voted upon and approved at the Annual Meeting:

  • Item 1 (Election of Directors): Three Class II directors were elected to serve until the 2028 Annual Meeting.
    • Scott Myers: Elected with 43,014,172 votes FOR and 3,948,491 votes WITHHELD.
    • Karan Takhar: Elected with 30,655,734 votes FOR and 16,306,929 votes WITHHELD.
    • Luke Walker, M.D.: Elected with 36,599,420 votes FOR and 10,363,243 votes WITHHELD.
  • Item 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved with 58,100,230 votes FOR and 10,761 votes AGAINST.
  • Item 3 (Executive Compensation): The advisory approval of named executive officer compensation was approved with 29,474,720 votes FOR and 17,374,784 votes AGAINST.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the specific reasons for the significant number of votes withheld for Karan Takhar (16.3 million) compared to other nominees.
  • Confirm the split in the advisory vote on executive compensation, where approximately 37% of voting shares voted against the proposal.
  • Review the definitive proxy statement filed on April 30, 2025, for detailed background on the director nominees and compensation policies.

Notizie